Nanomedicine ZPH is on the cusp of transitioning from a niche treatment for breast cancer to a groundbreaking, multi-cancer treatment platform.
The "product-led pitch" or a "solution-first approach”:
Nanomedicine ZPH is on the cusp of transitioning from a niche treatment for breast cancer to a groundbreaking, multi-cancer treatment platform. Combination therapies with ZPH technology can be a key to maximize its effectiveness in diverse hard-to-treat cancers.
Nanomedicine & Nanodrugs ZPH GmbH | Deutschland
-----------------------------------------------------------------
#CompetitiveEdge of “broad-spectrum” anti-cancers, is the power to treat multiple cancer types, rather than being limited to a single type of cancer.
Examples of broad-spectrum anti-cancer drugs that are used to treat a variety of cancers, including #BreastCancer:
1. #Keytruda (#Pembrolizumab)
• Manufacturer: Merck & Co.
• Annual Sales Peak: $14.38 billion in 2022
• Mechanism of Action: PD-1 inhibitor (immune checkpoint inhibitor)
• Cancers Treated: Breast cancer, non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, classical Hodgkin lymphoma, urothelial carcinoma, gastric cancer, and more.
2. #Opdivo (#Nivolumab)
• Manufacturer: BristolMyersSquibb
• Annual Sales Peak: $8.4 billion in 2022
• Mechanism of Action: PD-1 inhibitor (immune checkpoint inhibitor)
• Cancers Treated: Breast cancer, NSCLC, melanoma, renal cell carcinoma, classical Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, and more.
3. #Herceptin (#Trastuzumab)
• Manufacturer: Genentech/#Roche
• Annual Sales Peak: $7.4 billion in 2018
• Mechanism of Action: HER2 receptor antagonist
• Cancers Treated: HER2-positive breast cancer, HER2-positive gastric cancer.
4. #Avastin (#Bevacizumab)
• Manufacturer: Genentech/Roche
• Annual Sales Peak: $7.1 billion in 2018
• Mechanism of Action: VEGF inhibitor (angiogenesis inhibitor)
• Cancers Treated: Breast cancer, colorectal cancer, NSCLC, glioblastoma, renal cell carcinoma, ovarian cancer, and cervical cancer.
5. #Imfinzi (#Durvalumab)
• Manufacturer: AstraZeneca
• Annual Sales Peak: $2.0 billion in 2022
• Mechanism of Action: PD-L1 inhibitor (immune checkpoint inhibitor)
• Cancers Treated: Breast cancer, NSCLC, urothelial carcinoma, and small cell lung cancer (SCLC).
6. #Lenvima (#Lenvatinib)
• Manufacturer: Eisai
• Annual Sales Peak: $1.5 billion in 2020
• Mechanism of Action: Multiple receptor tyrosine kinase inhibitor
• Cancers Treated: Breast cancer, hepatocellular carcinoma, renal cell carcinoma, thyroid cancer, and endometrial cancer.
